RT Journal Article
SR Electronic
A1 Summers, Jaye
T1 EXPEDITION EXT
JF MD Conference Express
YR 2015
FD SAGE Publications
VO 15
IS 9
SP 15
OP 17
DO 10.1177/1559897715588277
UL http://mdc.sagepub.com/content/15/9/15.abstract
AB Patients with mild Alzheimer’s disease enrolled in EXPEDITION EXT had already received 80 weeks of treatment with either solanezumab or placebo. Utilizing a unique approach to the delayed-start model, researchers report that cognitive and instrumental function outcomes in delayed-start patients did not catch up to those in early-start patients, supporting the benefit of initiating treatment as early as possible.